loans, pursuant to § 225.28(b)(1) of Regulation Y.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166–2034:

1. Peoples Home Holding, Inc., Greenbrier, Arkansas; to become a bank holding company by acquiring 80 percent of the voting shares of The Peoples Bank, Portland, Arkansas.

C. Federal Reserve Bank of San Francisco (Maria Villanueva, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105–1579:

1. Cascade Financial Corporation, Everett, Washington; to become a bank holding company by acquiring 100 percent of the voting shares of Cascade Bank, Everett, Washington.

Board of Governors of the Federal Reserve System, June 4, 2001.

Robert deV. Frierson

Associate Secretary of the Board.

[FR Doc. 01–14367 Filed 6–6–01; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 22, 2001.

A. Federal Reserve Bank of Boston (Richard Walker, Community Affairs Officer) 600 Atlantic Avenue, Boston, Massachusetts 02106-2204:

1. Camden National Corporation, Camden, Maine; to acquire Acadia Trust, National Association, Portland, Maine, and thereby engage in trust company activities, pursuant to § 225.28(b)(5) of Regulation Y, and Gouws Capital Management, Inc., Portland, Maine, and thereby engage in investment advisory services, pursuant to § 225.28(b)(6) of Regulation Y.

Board of Governors of the Federal Reserve System, June 4, 2001.

Robert deV. Frierson

Associate Secretary of the Board.

[FR Doc. 01–14366 Filed 6–6–01; 8:45 am]

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anesthetic and Life Support Drugs Advisory Committee Meeting; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is canceling the meeting of the Anesthetic and Life Support Drugs Advisory Committee scheduled for June 14 and 15, 2001. The meeting was announced in the **Federal Register** of May 3, 2001 (66 FR 22240). It will be rescheduled at a later date.

FOR FURTHER INFORMATION CONTACT: Kimberly Topper, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12529.

Dated: May 31, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–14293 Filed 6–6–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[HCFA–R–118]

Agency Information Collection Activities: Submission for OMB Review; Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, has submitted to the Office of Management and Budget (OMB) the following proposal for the collection of information. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Extension of a currently approved collection; *Title of Information Collection:* Peer Review Organization Contracts: Solicitation of Statements of Interest from In-State Organizations, General Notice and Supporting Regulations in 42 CFR 475; *Form No.:* HCFA–R–118 (OMB# 0938–0526); *Use:* This notice is a solicitation of sources sought for the procurement of medical review services. The information is require for potential contractors to demonstrate that they meet the statutory requirements as Peer Review Organizations. Compliance with these requirements is voluntary.; *Frequency:* As needed; *Affected Public:* Business or other for-profit; *Number of Respondents:* 53 *Total Annual Responses:* 53; *Total Annual Hours:* 1 hour.

To obtain copies of the supporting statement for the proposed paperwork collections referenced above, access HCFA's web site address at http://www.hcfa.gov/regs/prdact95.htm, or E-mail your request, including your address and phone number, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to

the OMB Desk Officer designated at the following address: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: May 30, 2001.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA, Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards.

[FR Doc. 01–14370 Filed 6–6–01; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health & Human Development (NICHD): Opportunity for Cooperative Research and Development Agreement (CRADA)

SUMMARY: The National Institute of Child Health & Human Development is seeking at least one Collaborator to participate in a CRADA to develop computer software that will assist in the diagnostic and clinical management of amenorrhea.

DATES: On or before August 6, 2001, interested parties should send informal written notice to the Technology Transfer Branch of the National Cancer Institute (NCI TTB), acting on behalf of NICHD, of the intent to file a formal proposal. Formal proposals must be submitted to the NCI TTB on or before September 5, 2001. Proposals submitted after September 5, 2001 will be considered, but only after any and all proposals submitted within the ninety-day period.

ADDRESSES: Inquiries and proposals regarding this opportunity should be addressed to: Bruce D. Goldstein, NCI Technology Transfer Branch, Executive Plaza South, 6120 Executive Blvd., Suite 450, Rockville, Maryland, 20852 (Phone 301–496–0477, Fax # 301–402–2117). Scientific questions should be addressed to: Dr. Lawrence Nelson, Head, NICHD Gynecologic Endocrinology Unit, Developmental Endocrinology Branch, Building 10, Room 10N262, Bethesda, MD 20892–1862 (Phone (direct) 301–402–6608; Phone (office) 301–496–4686; Fax 301–402–0574; email *Lawrence__Nelson@nih.gov*).

SUPPLEMENTARY INFORMATION: A CRADA is the anticipated joint agreement to be entered into by NICHD and a collaborator pursuant to the Federal Technology Transfer Act of 1986 (15 U.S.C. 3710a), as amended. A CRADA is an agreement designed to enable certain collaborations between Government laboratories and non-Government laboratories. It is not a grant, and is not a contract for the procurement of goods/services. The NICHD is prohibited from transferring funds to a CRADA collaborator.

Under a CRADA, the NICHD can offer the selected collaborator access to facilities, staff, materials, and expertise. The collaborator may contribute facilities, staff, materials, expertise, and funding to the collaboration. A CRADA collaborator may elect an option to an exclusive or non-exclusive license to Government intellectual property rights arising under the CRADA, and may qualify as an inventor or co-inventor of new technology developed under the CRADA. Any party is eligible to participate; however, as between two or more sufficient, overlapping research proposals (where the overlap cannot be cured), the NICHD, as specified in 15 U.S.C. 3710a(c)(4), will give special consideration to small businesses, and will give preference to business units located in the U.S. that agree that products either embodying inventions made under the CRADA or produced through the use of such inventions will be manufactured substantially in the United States. In all other respects, the decision whether to begin negotiating a particular CRADA will turn on how well the proposal addresses the selection criteria below and how closely the proposed research matches the research interests of the NICHD.

The NICHD's general objectives for all CRADAs are the rapid publication of research findings, and the timely commercialization of prognostic, diagnostic, or therapeutic products. Specific CRADA research goals will be tailored to the particular needs of the NICHD laboratory, the expertise of the collaborator and NICHD, and any proprietary technology the collaborator and/or NICHD brings to the project. Under the present opportunity, the goals of the CRADA are anticipated to include, but not be limited to, the development of the following technology:

- Development of one or more software packages for analyzing patient data in cases of amenorrhea;
- Examination of possible automated processes for conducting differential diagnoses of conditions causing amenorrhea; and
- Development of improved tools for diagnosing conditions causing amenorrhea, to be used by clinicians in a clinical setting.

The software to be developed will be able to collect standardized data from patients with amenorrhea at the point of care. This system will be used to collect research data that will accurately characterize the clinical presentation of a broad range of disorders that may present with a chief complaint of amenorrhea. As this data is collected and analyzed the findings will be used to update the software. This iterative process will build an effective instrument that eventually can be used by caregivers at the point of patient contact to assist in the diagnosis and management of amenorrhea. After the system has been fully validated in a research setting this ''working model'' may be modified so as to collect basic screening data from women with amenorrhea in preparation for a visit to their health care provider. Thus, the development of a successful system will depend heavily on insight and experience on how to best meet the needs of the health care consumer as well as the health care provider.

A strategy should be developed to collect the patient data, link it to the pertinent published medical literature across disciplines, and provide a process for guided investigation and clinical decision making. Strategies should also be developed to employ the system for patient education, disease prevention, and health promotion.

The term of the CRADA(s) will be up to five (5) years, depending on the proposal(s). Applicants are encouraged to recommend in the written proposal alternative, additional applications and technologies to be developed.

Anticipated Party Contributions

The role of NICHD may include the following:

(1) Plan research studies, interpret research results, and jointly publish the conclusions with the collaborator;

(2) Provide collaborator with access to existing NICHD research data (both already collected and yet to be collected);

(3) Provide staff, expertise, & materials for the development and testing of promising products; and

(4) Provide work space and equipment for testing of any prototype systems developed.

The role of the successful collaborator will include the following:

(1) Provide significant intellectual, scientific, and technical expertise in the development and manufacture of relevant products;

(2) Plan research studies, interpret research results, and jointly publish the conclusions with NICHD;